buprenorphine extended-release · SUBLOCADE
Small molecule
Evidence outlook
Approved: Opioid Use Disorder
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Moderate to severe opioid use disorder in adults stabilised on a transmucosal buprenorphine product
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01738503 NCT01738503 · Opioid Use Disorder This was an open-label, non-randomized, uncontrolled Phase 2 study: 89 participants were treated across six RBP-6000 dose groups with no placebo or comparator arm and no masking, and the primary endpoints were pharmacokinetic measures (buprenorphine/norbuprenorphine plasma concentrations) plus counts of treatment-emergent adverse events rather than a clinical efficacy outcome. With no randomization, no blinding, and no control group, the design cannot support strong or even moderate conclusions about how well the drug works; the results describe drug levels and tolerability only. Registry: NCT01738503 | 2 | Participants With Treatment-Emergent Adverse Events (TEAEs) (Days -14 to -1 (Subutex treatment), Days 1-316 (RBP-6000 treatment)); Buprenorphine PK: % Fluctuation (Day -1, Days 1-29, 85-113, 141-197); Buprenorphine PK: Area Under Plasma Concentration Time Curves (AUC) (Day -1, Days 1-29, 85-113, 141-197); Buprenorphine PK: Average Plasma Concentration (Cavg) (Day -1, Days 1-29, 85-113, 141-197); Buprenorphine PK: Maximum Observed Plasma Concentration (Cmax) (Day -1, Days 1-29, 85-113, 141-197); Buprenorphine PK: Minimum Observed Plasma Concentration (Cmin) (Day -1, Days 1-29, 85-113, 141-197); Buprenorphine PK: Swing of Plasma Concentrations (Day -1, Days 1-29, 85-113, 141-197); Buprenorphine PK: Time to Maximum Buprenorphine Plasma Concentration (Tmax) (Day -1, Days 1-29, 85-113, 141-197); Buprenorphine PK: Accumulation Index in Terms of Area Under the Curve (Rac(AUC)) (Days 1-28, 85-113); Buprenorphine PK: Accumulation Index in Terms of Maximum Observed Plasma Drug Concentration (Rac(Cmax)) (Days 1-28, 85-113); Buprenorphine PK: Apparent Clearance at Steady-State (CLss/F) Following Injections 4 and 6 (Days 85-113, 141-169); Buprenorphine PK: Area Under Plasma Concentration Time Curve From Time Zero Of Injection 4 (AUC0-∞) (Days 85-113); Buprenorphine PK: Terminal Phase Half Life (t1/2) Calculated For Injection 4 (Days 85-113); Norbuprenorphine PK: % Fluctuation (Day -1, Days 1-29, 85-113, 141-197); Norbuprenorphine PK: Area Under Plasma Concentration Time Curves (AUC) (Day -1, Days 1-29, 85-113, 141-197); Norbuprenorphine PK: Average Plasma Concentration (Cavg) (Day -1, Days 1-29, 85-113, 141-197); Norbuprenorphine PK: Maximum Observed Plasma Concentration (Cmax) (Day -1, Days 1-29, 85-113, 141-197); Norbuprenorphine PK: Minimum Observed Plasma Concentration (Cmin) (Day -1, Days 1-29, 85-113, 141-197); Norbuprenorphine PK: Swing of Plasma Concentrations (Day -1, Days 1-29, 85-113, 141-197); Norbuprenorphine PK: Time to Maximum Buprenorphine Plasma Concentration (Tmax) (Day -1, Days 1-29, 85-113, 141-197); Norbuprenorphine PK: Accumulation Index in Terms of Area Under the Curve (Rac(AUC)) (Days 1-28, 85-113); Norbuprenorphine PK: Accumulation Index in Terms of Maximum Observed Plasma Drug Concentration (Rac(Cmax)) (Days 1-28, 85-113); Norbuprenorphine PK: Area Under Plasma Concentration Time Curve From Time Zero Of Injection 4 and 6 (AUC0-∞) (Days 85-113, 141-197); Norbuprenorphine PK: Terminal Phase Half Life (t1/2) Calculated For Injection 4 (Days 85-113, 141-197) 2014-05 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
View 4 more trials
NCT02559973 NCT02559973 · Opioid Use Disorder Registry: NCT02559973 | 1 | Area Under the Concentration-Time Curve from Study Day 1 to Day 29 (AUC0-28days) of Buprenorphine; Maximum Observed Plasma Concentration (Cmax) of Buprenorphine (Day 1 to Day 57) 2016-02 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT02357901 NCT02357901 · Opioid Use Disorder The trial randomized 504 participants after run-in (194, 196, and 99 in the two RBP-6000 and pooled placebo groups used for efficacy analysis), with participants, care providers, and investigators blinded and placebo injections as the comparator. Its primary clinical abstinence endpoint was statistically superior for both RBP-6000 regimens versus placebo (p<0.0001 for each comparison), supporting strong evidence from this well-controlled trial. Registry: NCT02357901 | 3 | Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From Week 5 Through Week 24 (Weekly from Weeks 5-24) 2016-04-29 | Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From Week 5 Through Week 24 (Weekly from Weeks 5-24): RBP-6000 300mg/100mg — >=0%: 194 Participants; >=10%: 139 Participants; >=20%: 115 Participants; >=30%: 101 Participants; >=40%: 90 Participants; >=50%: 86 Participants; >=60%: 78 Participants; >=70%: 66 Participants; >=80%: 55 Participants; >=90%: 41 Participants | RBP-6000 300mg/300mg — >=0%: 196 Participants; >=10%: 126 Participants; >=20%: 111 Participants; >=30%: 101 Participants; >=40%: 90 Participants; >=50%: 82 Participants; >=60%: 70 Participants; >=70%: 67 Participants; >=80%: 57 Participants; >=90%: 48 Participants | Combined Placebo — >=0%: 99 Participants; >=10%: 11 Participants; >=20%: 7 Participants; >=30%: 6 Participants; >=40%: 6 Participants; >=50%: 4 Participants; >=60%: 4 Participants; >=70%: 2 Participants; >=80%: 2 Participants; >=90%: 2 Participants | Reliable signal | link ↗ |
NCT02510014 NCT02510014 · Opioid Use Disorder This open-label, single-group Phase 3 study had no randomization, no blinding and no comparator arm. Of 775 participants who entered a sublingual buprenorphine run-in, 669 went on to receive open-label monthly extended-release buprenorphine injections; 508 of the 775 were newly enrolled rather than continuing from the earlier trial RB-US-13-0001. Every primary endpoint measured safety or tolerability, reported descriptively: at least one treatment-emergent adverse event occurred in 302 of 412 de novo and 145 of 257 roll-over participants who received injections, with no deaths. The study therefore describes the injection's safety profile without testing its efficacy against a control. Registry: NCT02510014 | 3 | Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period (Day 1 to Week 49 (De novo arm); Day 1 to Week 25 (Roll-over arm)); Percentage Change From Baseline to End of Study (Weeks 25 and 49) in Vital Signs (Baseline (Day 1 predose) End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)); Shifts in Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Most Severe Assessment During the Treatment Period (Baseline (Screening visit, days -21 to -15), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)); Worst Local Injection Site Pain From Injections as Measured by Participant-Reported Visual Analog Scale (VAS) (De Novo Subjects: Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281 and 309 Roll-over Subjects: Days 1, 29, 57, 85, 113, 141) 2017-01-31 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT04995029 NCT04995029 · Opioid Use Disorder Registry: NCT04995029 | 4 | Maintenance Phase: Percentage of Responders for Weekly Opioid Use Over Weeks 20 to 38; Induction Phase: Percentage of Participants Receiving Injection 2 at the Week 2 Visit 2024-06-26 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Opioid Use Disorder: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Buprenorphine Extended-Release (SUBLOCADE): this drug | Approved | Small molecule | Mu-opioid receptor (partial agonist) | Weak signal | Featured results are non-efficacy only in this race | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SUBLOCADE (buprenorphine extended-release) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
January 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent